Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-Vrd) Transplant-Eligible (TE) Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study Pieter Sonneveld , Philippe Moreau , Meletios A. Dimopoulos , Hang Quach , P. Joy Ho , Meral Beksac , Cyrille Hulin , Elisabetta Antonioli , Xavier Leleu , Silvia Mangiacavalli , Aurore Perrot , Michele Cavo , Angelo Belotti , Annemiek Broijl , Francesca Gay , Roberto Mina , Inger S. Nijhof , Niels W. C. J. van de Donk , Eirini Katodritou , Fredrik Schjesvold , Anna Sureda Balari , Laura Rosinol , Michel Delforge , Wilfried Roeloffzen , Christoph Driessen , Annette Vangsted , Hermann Einsele , Andrew Spencer , Roman Hajek , Artur Jurczyszyn , Sarah Lonergan , Yanfang Liu , Jianping Wang , Diego Vieyra , Emilie M. J. van Brummelen , Veronique Vanquickelberghe , Anna Sitthi-Amorn , Carla J. de Boer , Robin Carson , Joan Blade , Mario Boccadoro , Paula Rodriguez-Otero CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2024）
Key words
MM, multiple myeloma, CD38, minimal residual disease, maintenance, daratumumab, phase
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
